Research Analysts Set Expectations for argenx Q1 Earnings

argenx SE (NASDAQ:ARGX) – Research analysts at Leerink Partnrs issued their Q1 2025 earnings estimates for shares of argenx in a report issued on Friday, February 28th. Leerink Partnrs analyst T. Smith anticipates that the company will post earnings per share of $2.04 for the quarter. The consensus estimate for argenx’s current full-year earnings is $3.13 per share. Leerink Partnrs also issued estimates for argenx’s Q2 2025 earnings at $2.40 EPS, Q3 2025 earnings at $2.71 EPS and Q4 2025 earnings at $3.02 EPS.

argenx (NASDAQ:ARGX) last posted its quarterly earnings data on Thursday, February 27th. The company reported $1.58 earnings per share (EPS) for the quarter, beating the consensus estimate of $0.98 by $0.60. The firm had revenue of $761.22 million for the quarter, compared to the consensus estimate of $678.52 million. argenx had a negative return on equity of 1.45% and a negative net margin of 2.11%.

Other equities analysts also recently issued reports about the company. Deutsche Bank Aktiengesellschaft downgraded argenx from a “hold” rating to a “sell” rating in a research report on Friday, January 17th. William Blair reissued an “outperform” rating on shares of argenx in a report on Friday, February 28th. Wells Fargo & Company upped their price objective on argenx from $723.00 to $741.00 and gave the stock an “overweight” rating in a research report on Friday, February 28th. Wedbush reaffirmed an “outperform” rating and issued a $655.00 price target on shares of argenx in a report on Tuesday, December 3rd. Finally, Evercore ISI boosted their price objective on shares of argenx from $675.00 to $706.00 and gave the stock an “outperform” rating in a research report on Thursday, November 21st. One equities research analyst has rated the stock with a sell rating, two have given a hold rating, eighteen have assigned a buy rating and one has assigned a strong buy rating to the company’s stock. Based on data from MarketBeat.com, the stock has an average rating of “Moderate Buy” and an average target price of $662.83.

argenx Stock Down 0.2 %

argenx stock opened at $621.25 on Monday. The company’s 50 day moving average is $642.51 and its two-hundred day moving average is $591.91. The firm has a market cap of $37.75 billion, a PE ratio of -705.97 and a beta of 0.58. argenx has a 52-week low of $349.86 and a 52-week high of $678.21.

Hedge Funds Weigh In On argenx

A number of hedge funds have recently made changes to their positions in the business. FMR LLC lifted its position in argenx by 17.2% during the 4th quarter. FMR LLC now owns 5,618,222 shares of the company’s stock worth $3,455,207,000 after acquiring an additional 824,750 shares in the last quarter. Janus Henderson Group PLC raised its holdings in argenx by 0.4% in the third quarter. Janus Henderson Group PLC now owns 2,479,207 shares of the company’s stock valued at $1,343,797,000 after acquiring an additional 10,975 shares in the last quarter. Capital World Investors increased its holdings in argenx by 5.1% in the fourth quarter. Capital World Investors now owns 1,786,936 shares of the company’s stock valued at $1,099,002,000 after buying an additional 86,687 shares during the last quarter. RTW Investments LP lifted its holdings in argenx by 2.9% during the 4th quarter. RTW Investments LP now owns 673,497 shares of the company’s stock worth $414,201,000 after buying an additional 19,067 shares during the last quarter. Finally, Clearbridge Investments LLC lifted its holdings in argenx by 6.8% during the 4th quarter. Clearbridge Investments LLC now owns 629,828 shares of the company’s stock worth $387,344,000 after buying an additional 40,330 shares during the last quarter. Hedge funds and other institutional investors own 60.32% of the company’s stock.

argenx Company Profile

argenx SE, a biotechnology company, engages in the developing of various therapies for the treatment of autoimmune diseases in the United States, Japan, Europe, Middle East, Africa, and China. Its lead product candidate is efgartigimod for the treatment of patients with myasthenia gravis, immune thrombocytopenia, pemphigus vulgaris, generalized myasthenia gravis, chronic inflammatory demyelinating polyneuropathy, thyroid eye disease, bullous pemphigoid, myositis, primary sjögren’s syndrome, post-covid postural orthostatic tachycardia syndrome, membranous nephropathy, lupus nephropathy, anca-associated vasculitis, and antibody mediated rejection; ENHANZE SC; Empasiprubart for multifocal motor neuropath, delayed graft function, and dermatomyositis; and ARGX-119 for congenital myasthenic syndrome and amyotrophic lateral sclerosis.